Hello - thanks for asking your question.
Zelnorm (Tegaserod) increases the action of serotonin (a body chemical) in the intestines. This speeds the movement of stools (bowel movements) through the bowels. Tegaserod is used to treat severe, chronic, irritable bowel syndrome (IBS) in women who have constipation (not enough or hard bowel movements) as their main bowel problem, (constipation-predominant). Tegaserod has not been shown to be helpful for men with irritable bowel syndrome.
This is from the Zelnorm.com site:
"Adverse events reported significantly more often with Zelnorm than with placebo were headache (15% vs 12%) and diarrhea (9% vs 4%). Zelnorm is contraindicated in those patients with severe renal impairment; moderate or severe hepatic impairment; a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions; or a known hypersensitivity to the drug or any of its excipients. Zelnorm should not be initiated in patients who are currently experiencing, or frequently experience, diarrhea. Zelnorm should be discontinued immediately in patients with new or sudden worsening of abdominal pain."
http://www.zelnorm.com/hcp/about/zelnorm/importsafety.jsp
Regarding cardiovascular effects specfically:
"Although the events reported occurred during treatment with Zelnorm, they were not necessarily caused by it:
Cardiovascular: hypotension, angina pectoris, syncope, arrhythmia, bundle branch block, supraventricular tachycardia"
http://www.zelnorm.com/hcp/about/zelnorm/tolerability.jsp
Zelnorm is not typically prescribed for GERD. Looking at Medline, there is one very small study that suggested that it *may* have a decrease in post-prandial acid secretion:
"Tegaserod in a dose of 1 mg/day causes a significant decrease in postprandial oesophageal acid exposure. The reduction in oesophageal acid exposure with tegaserod treatment may result from enhanced oesophageal acid clearance, improved gastric emptying, and/or reduced transient lower oesophageal sphincter relaxations."
Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000 Nov;14(11):1503-9.
I would strongly suggest that you follow this up with your personal physician or gastroenterologist.
I stress that this answer is not intended as and does not substitute for medical advice - please see your personal physician for further evaluation of your individual case.
Thanks,
Kevin, M.D.
Links:
Zelnrom.com
http://www.zelnorm.com/index.jsp?checked=y
http://www.zelnorm.com/hcp/about/zelnorm/tolerability.jsp